Recombinant Mouse Serum Paraoxonase/Arylesterase 1 (PON1)

Name: Recombinant Mouse Serum Paraoxonase/Arylesterase 1 (PON1)
Brand: Beta LifeScience
SKU: BLC-02658P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: High-quality recombinant proteins, Other recombinant proteins, Recombinant proteins fall special offers - full-length proteins, Recombinant proteins fall special offers - tag-free proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Mouse Serum Paraoxonase/Arylesterase 1 (PON1) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P52430
Target Symbol	PON1
Synonyms	Pon1; Pon; Serum paraoxonase/arylesterase 1; PON 1; EC 3.1.1.2; EC 3.1.1.81; EC 3.1.8.1; Aromatic esterase 1; A-esterase 1; Serum aryldialkylphosphatase 1
Species	Mus musculus (Mouse)
Expression System	E.coli
Tag	Tag-Free
Target Protein Sequence	AKLLALTLVGLVLALYKNHRSSYQTRLNAFREVTPVELPNCNLVKGIETGAEDLEILPNGLTFFSTGLKYPGIKSFDPSKPGKILLMDLNKKEPAVSELEIIGNTLDISSFNPHGISTFTDEDNTVYLLVVNHPDSSSTVEVFKFQEEERSLLHLKTITHELLPSINDIAAIGPESFYATNDHYFADPYLRSWEMYLGLSWSNVVYYSPDKVQVVAEGFDFANGIGISLDGKYVYIAELLAHKIHVYEKHANWTLTPLKVLNFDTLVDNISVDPVTGDLWVGCHPNGMRIFFYDAENPPGSEVLRIQNILSEDPKITVVYAENGTVLQGTTVASVYKGKLLIGTVFHKALYCDL
Expression Range	2-355aa
Protein Length	Full Length of Mature Protein
Mol. Weight	39.4 kDa
Research Area	Neuroscience
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Hydrolyzes the toxic metabolites of a variety of organophosphorus insecticides. Capable of hydrolyzing a broad spectrum of organophosphate substrates and lactones, and a number of aromatic carboxylic acid esters. Mediates an enzymatic protection of low density lipoproteins against oxidative modification.
Subcellular Location	Secreted, extracellular space.
Protein Families	Paraoxonase family
Database References	KEGG: mmu:18979 STRING: 10090.ENSMUSP00000002663 UniGene: Mm.237657
Tissue Specificity	Plasma, liver, kidney, heart, brain, small intestine and lung. In the plasma, associated with HDL.

Gene Functions References

Study shows that PON1 can significantly relieve airway inflammation and airway remolding in asthma mice, and inhibit the secretion of LPS induced macrophage inflammatory cytokines and the proliferation of lung fibroblasts. These results suggest that PON1 may be involved in airway inflammation and remodeling in asthma. PMID: 28657647
PON1 overexpression protects against AAA progression by reducing oxidative stress, apoptosis and inflammation PMID: 26993251
Paraoxonase 1 (PON1) influence circadian gene expression and period length PMID: 27010443
results suggest that Hyperhomocysteinemia plays an intricate role in dysfunctional HDL, owing to the lack of PON1. This contributes to vascular endothelial impairment and atherosclerosis. PMID: 26176406
Maternal PON1 status modulates the effects of repeated gestational chlorpyrifos oxon exposure on fetal-brain gene expression and on inhibition of both maternal and fetal biomarker enzymes. PMID: 25070982
5,6-dihydroxyeicosatrienoate-1,5-lactone, a stable metabolite of arachidonic acid, is a potential substrate for PON1. PMID: 25958017
HDL (mostly HDL3), stimulates PON1 antiatherogenic activities in mouse macrophages. PMID: 25230879
Findings suggest that Pon1 interacts with diverse cellular processes from energy metabolism and anti-oxidative defenses to cell cycle, cytoskeleton dynamics, and synaptic plasticity essential for normal brain homeostasis PMID: 24844689
The study demonstrated a significant decline in PON1 activity which correlates with increased LDL oxidation after 8 months of age in Wistar rats. PMID: 24971380
PON1 plays a protective role against hepatic derangements, secondary to fat and cholesterol overnutrition. PON1 deficiency is associated with oxidative stress and metabolic alterations leading to liver steatosis. PMID: 23448543
PON1 is not essential for normal development, function, ageing, and the defense against light damage of the mouse retina. PMID: 25028362
Suggest that PON1 decreases sustained pro-inflammatory reactions, which subsequently can attenuate plaque progression. PMID: 23582715
PON1 plays a beneficial role in glucose regulation and metabolism and may serve as an important tool in diabetes control. PMID: 23639858
PON1 activity was found to be increased in diabetic mice after administration of aqueous Murraya koenigii leaves extract. PMID: 23207871
Pon1 protects mice against Hcy-thiolactone neurotoxicity by hydrolyzing it in the brain. PMID: 22406444
PON1 is a potent anti-diabetic enzyme that exerts this protection against diabetes through its antioxidative, as well as via its insulin stimulation properties on beta-cells. PMID: 21862013
antiatherosclerotic properties of HDL can be attributed to two major mechanisms of action of PON1: protecting macrophages from TG-induced oxidative modification and (ii) reduction of peroxide levels in oxidized TGs. PMID: 21530644
PON1 status plays a critical role in modulating the effects of neonatal chlor- pyrifos oxon exposure in the developing brain. PMID: 21673326
PON1 status modulates the ability of CaE to detoxicate OP compounds from specific mixed insecticide exposures [review] PMID: 20221870
analysis of PON1 and oxidative stress in human sepsis and an animal model of sepsis [review] PMID: 20221873
paraoxonase 1 has a role in the detoxification of homocysteine thiolactone [review] PMID: 20221875
PON1 is affectd by HDL mimetic peptide 4F [review] PMID: 20221879
Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones. PMID: 21044894
PON1 proteins were present in the vast majority of tissues investigated. mRNA for these proteins was also expressed in most of these tissues suggesting local production and the ability to respond in situ to inflammatory stimuli. PMID: 20931267
PON1 deficiency in mice is associated with decreased macrophage SR-BI expression, decreased cellular HDL binding, and consequently the loss of HDL-mediated cytoprotection against apoptosis PMID: 20149374
PON1 regulates adrenal corticosterone biosynthesis at two levels: (a) via an accessory role in HDL binding properties, and (b) a supportive role in SR-BI expression and cholesteryl ester supply to the cells. PMID: 20189567
Paraoxonase 1 protects high-density lipoprotein integrity and function in Paraoxonase 1 transgenic mice PMID: 11798161
antioxidant PON-1 is regulated at the mRNA level in a gender-specific manner by proinflammatory LPS and anti-inflammatory dexamethasone PMID: 12654470
mouse PON1 is quantitatively associated with high density lipoproteins PMID: 14703510
liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia PMID: 15213869
Incubation of isolated human apoA-II with control mouse plasma at 37 degrees C decreased PON1 activity and displaced the enzyme from HDL. PMID: 15388641
PON1 may contribute to the attenuation of atherosclerosis development by its ability to act on macrophage phospholipids PMID: 15721011
genotypes and risk of insecticide toxicity PMID: 15977192
paraoxonase interruption of bacterial communication represents a novel mechanism to modulate quorum-sensing by bacteria PMID: 16260097
Hepatic PON1 and CYP7A1 mRNA expression is repressed by bile acids via FXR-mediated induction of FGF15 PMID: 16284190
the catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux PMID: 16407304
SR-BI deficiency results in a reduced activity of the antioxidant enzyme PON1 and a significant increase in oxidative stress, potentially contributing to the proatherogenic effect of SR-BI deficiency. PMID: 17717299
Our data revealed significant vascular changes in adhesion, oxidative stress, and thrombotic tendencies in Pon1(-/-) mice in the absence of hyperlipidemia and systemic inflammation. PMID: 18402813
Serum albumin is as efficient as paraxonase in the detoxication of paraoxon at toxicologically relevant concentrations. PMID: 18597495
Pon1 does not show a parent-of-origin preference in its allelic expression, but has dramatic variations in allele-specific expression occurring throughout development PMID: 18678600
N-acetylcysteine may be effective in the treatment of colitis through its up-regulating PON1 and scavenging oxygen-derived free radicals. PMID: 19034653
The anti-atherogenic biological activities were studied in vitro using serum or cell cultures, and also in vivo, using PON 1/2/3 knockout or transgenic mice, as well as humans - healthy volunteers and atherosclerotic patients. PMID: 19082953
Knockout and transgenic PON1 mice were used to study the toxicity of organosphosphorus pesticides. PMID: 19371602
Studies have demonstrated the antioxidative and atheroprotective effects of PON1. PMID: 19474728
Reduced PON1 activity may be involved in the pathogenesis of asthma. PMID: 19556304

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.